Medical Journals

Inhibition of Phosphorylation of P38 Mapk Involved in the Protection of Nephropathy by Emodin in Diabetic Rats.

Authors:
  • Wang Jinping
  • Huang Heqing
  • Liu Peiqing
  • Tang Futian
  • Qin Jia
  • Huang Wenge
  • Chen Fengying
  • Guo Fenfen
  • Liu Weihua
  • Yang Bing

From: Lab of Pharmacology and Toxicology, School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou, 510080, China.

European journal of pharmacology

  • Publish Date: Dec 2006
  • ISSN: 0014-2999
  • Volume: 553
  • Issue: 1-3
  • Pages: 297-303
  • Medium: Print
  • Language: English
  • Citation (JAMA): Wang Jinping, Huang Heqing, Liu Peiqing, et al. Inhibition of Phosphorylation of P38 Mapk Involved in the Protection of Nephropathy by Emodin in Diabetic Rats.. Eur. J. Pharmacol. Dec 2006;553:297-303

Abstract

To explore the protection of emodin on renal dysfunction in the streptozotocin-induced diabetic rats with nephropathy and the role of p38 mitogen-activated protein kinase (p38 MAPK) signal transduction pathway in this protection. 30 male Spraque-Dawley rats were randomly divided into control group, model group and emodin group. The rats in the model group and emodin group were administered with streptozotocin (60 mg/kg) to induce diabetes. 40 mg/kg/day of emodin were orally given to the rats in emodin group. The rats in other groups were only given solvent. Biochemical index were analysed by oxidase and oxidase dynamical enzyme method. Glomerular area and volume were determined quantitatively by using Image Analysis System. Western blotting and immunohistochemical staining was used to detect the total p38 MAPK, phosphorylated p38 MAPK, phosphorylated cAMP response element binding protein (CREB) and fibronectin. The average kidney weight/body weight, glomerular area, glomerular volume and all biochemical indexes significantly increased in model group as compared to the control group (P<0.05), while the average body weight decreased. The expressions of phosphorylaed p38 MAPK, phosphorylated CREB and fibronectin increased by 1.98-fold, 1.94-fold and 1.96-fold respectively in model group compared with those in the control group (P<0.05). Emodin markedly decreased the average kidney weight/body weight, glomerular area, glomerular volume and all biochemical indexes (P<0.05), having a weak action on the level of blood glucose. The expressions of phosphorylated p38 MAPK, phosphorylated CREB and fibronectin also significantly downregulated in emodin group compared with those in model group (P<0.05). Emodin was efficient to ameliorate renal dysfunction in diabetic nephropathy rats probably by its inhibition of the activation of p38 MAPK pathway and downregulation of the expression of fibronectin.

Mesh Headings (Keywords): Actins, Animals, Blood Glucose, Blotting, Western, Body Weight, Cyclic AMP Response Element-Binding Protein, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Emodin, Enzyme Inhibitors, Fibronectins, Immunohistochemistry, Kidney, Kidney Function Tests, Male, Organ Size, Phosphorylation, Rats, Rats, Sprague-Dawley, Signal Transduction, p38 Mitogen-Activated Protein Kinases


Check for Full Text / PubMed Unique Identifier (PMID): 17074319


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.